



AlphaRx

Symbol: ALRX  
Exchange: OTCBB

Shares Outstanding  
92,371,192

52 Week Range  
\$.05 - \$.28

Market Capitalization  
\$3,971,961

### Investor Relations Contact

AGORACOM Investor Relations

### Email

ALRX@Agoracom.com

### Website

www.Agoracom.com

www.AlphaRx.com

## AlphaRx Inc.

Development of effective and innovative medicines and drug delivery platforms

# Investor Fact Sheet

(as of March 10, 2009)

## OVERVIEW

### THE COMPANY

- Multi Billion Dollar Market Opportunity
- Proprietary High Value Nano Drug Delivery Platform
- Excellent Potential for Stockholder Value Increase

AlphaRx is a publicly traded company listed on the OTCBB (Symbol: ALRX)

AlphaRx is a specialty pharmaceutical company utilizing site-specific nanoparticulate drug delivery technology to develop novel formulations of drugs that are insoluble or poorly soluble in water, or have yet to be administrable to the human body with an acceptable delivery method. Under the drug delivery program, the Company's product candidates address various pharmaceutical markets, including osteoarthritis, ocular infection/inflammation, pneumonia, tuberculosis and pain management.

The Company also discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases and neurodegenerative diseases. Under the drug discovery program, the Company's goal is to move one product candidate for a significant indication into the clinic in 2008.

Currently, the Company has one pharmaceutical product launched in the Mexican market and two over-the-counter products launched in the Hong Kong market.

### VANSOLIN™ – Lead Product

➡ In Pivotal Animal Study

**Goal: 1st line I.V. treatment for serious infections**

- **Nano Delivery Platform:** Targeted delivery of Vancomycin to the site of inflammation i.e. lung tissue.
- **Potential Benefits:** Improved efficacy (including MRSA), less dose, shorter treatment time.
- **Growing Market:** 30M treatment days.
- **FDA Approval:** Fast track.
- **Market Opportunity: US\$3.6 Billion.**

### RECENT NEWS

- AlphaRx Initiates Indaflex(TM) China Registration
- AlphaRx Seeks Listing with TSX Venture Exchange


### INDAFLEX™ PHASE II

Dr. Lee S. Simon, former FDA Director commented: "Indaflex™ has the potential to fulfill the need for an effective, tolerable and safer alternative to either oral non-selective NSAIDs or Cox-2 selective inhibitors for the treatment of osteoarthritis of the knee, as well as other diseases and disorders which are associated with localized pain and inflammation."

### ARX828 iNOS Inhibitor

**Large Market Indications:** A novel, orally administered, small molecule with strong anti-inflammatory activity. Potentially less side effects vs. anti-body based medicine.

### COMMON FORMS OF ARTHRITIS IN THE U.S.



# Investor Fact Sheet



## AlphaRx Inc.

Development of effective and innovative medicines and drug delivery platforms. All AlphaRx drug candidates were developed internally. AlphaRx has three U.S. patents issued, 10 U.S. patents pending and several foreign patents pending.

### Head Office

#### AlphaRx

168 Konrad Crescent  
Suite 200, Markham  
Ontario, Canada L3R 9T9

Phone: 905.479-3245  
Fax: 416.352-6120  
Email: info@AlphaRx.com

### Directors & Executive Team

Michael Lee, B.Sc  
*President*

Marcel Urbanc, C.A.,  
B.A.S, B.A

*Chief Financial Officer*

Joseph Schwarz, Ph.D.  
*Chief Scientist*

Michael Weisspapir,  
M.D., Ph.D.  
*Chief Medical Scientist*

[www.AlphaRx.com](http://www.AlphaRx.com)

## ROBUST PRODUCT PIPELINE


Product	Initial Indication	Market Value (Est.)*
Indaflex™***	Osteoarthritis	\$1.0B+
Vansolin™ NDS	Nosocomial Pneumonia	\$3.6B+
ARX828	Inflammation	\$3.0B+
ARX838**	Neurodegenerative	\$2.0B+
Azithromycin NDS	CAP Pneumonia	\$1.0B+
Streptomycin NDS	Tuberculosis	\$200M
<b>TOTAL</b>		<b>\$10.8 Billion+</b>

\*Source: Companies reports, market studies, and AlphaRx estimates

\*\*Partnered with Pharmaseed Ltd, Israel

\*\*\*Licensed to Proprius Pharmaceutical, San Diego

## MARKET SNAPSHOT



The material contained in this publication is for information purposes only and does not constitute an offer to sell or buy any security. The information is from sources we believe to be reliable, but we do not guarantee it; errors and omissions are inevitable. It is not all-inclusive. Do not rely on it as the sole source of information for making decisions.